For those who’d rather not read the whole story, here is its musical summary (via Prof. Daniel Palanker):
youtu.be/n51nloRy7zc?...

China is pursuing both invasive and non-invasive #BCI in parallel: much broader from the start than U.S. firms like #Neuralink or #Synchron.

But many Chinese ventures are still early-stage; matching U.S. clinical maturity will require a steep ramp-up.

Goals by 2027: Breakthrough in core #BCI tech

By 2030: 2-3 world-class companies, robust SMEs, broader medical & consumer use, supported by national standards & regulation

Already gaining investor momentum: stocks in companies like Nanjing Panda Electronics (+19%) & MicroPort NeuroScientific (+8%)